|
A phase 1/2 open-label, multicenter, dose escalation and expansion study of AVB-001, an intraperitoneally administered, cell-generated, human IL-2 immunotherapy in patients with platinum-resistant, high-grade, serous adenocarcinoma of the ovary, primary peritoneum, or fallopian tube. |
|
|
Consulting or Advisory Role - AstraZeneca; Bayer; BioAscent; Caris Life Sciences; Clovis Oncology; Curio Science; Eisai; EQRX; Genentech; Gerson Lehrman Group; GlaxoSmithKline; Immunogen; Lilly; Medscape; Merck; Mereo BioPharma; Mersana; NGM Biopharmaceuticals; Nuvectis Pharma; OncLive; Roche; Seagen; Targeted Oncology; Vaniam Group; Vincerx Pharma; Zentalis |
Research Funding - AstraZeneca (Inst); Avenge Bio (Inst); Bayer (Inst); Bio-Path Holdings, Inc (Inst); Clovis Oncology (Inst); GlaxoSmithKline (Inst); GOG Foundation (Inst); Mereo BioPharma (Inst); Novartis (Inst); OncXerna Therapeutics (Inst); Roche/Genentech (Inst); Zentalis (Inst) |
|
|
Stock and Other Ownership Interests - hC Bioscience |
|
Consulting or Advisory Role - Gimv; hC Bioscience; TigaTx |
Patents, Royalties, Other Intellectual Property - Dr. Yeku has a patent for MUC16 Directed Antibodies for therapeutic applications pending and a patent for Human Artificial Chromosomes for therapeutic applications pending. |
|
|
Research Funding - Bristol-Myers Squibb Foundation/Janssen; Gilead Sciences |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Avenge Bio |
|
|
|
Stock and Other Ownership Interests - Avenge Bio |
|
|
|
Stock and Other Ownership Interests - Avenge Bio |
|
|
Stock and Other Ownership Interests - Avenge Bio; Greenfire Bio |
Honoraria - Gerson Lehrman Group; Guidepoint Global |
Consulting or Advisory Role - Adicet Bio; Alkermes; Macrogenics; NuProbe; Theolytics |
Research Funding - Aravive (Inst); AstraZeneca (Inst); Avenge Bio (Inst); Bristol-Myers Squibb (Inst); immatics (Inst); Iovance Biotherapeutics (Inst); Lilly (Inst); Macrogenics (Inst); Merck (Inst); Pfizer (Inst); Xencor (Inst) |